Assistant Professor of Medicine
Member of the Duke Cancer Institute
Campus mail
Dept of Medicine, Box 31079 DUMC, Durham, NC 27710
Phone
(919) 684-8111
Email address
lindsay.magura@duke.edu
Education and Training
- Resident, Internal Medicine, Duke University School of Medicine, 2008 - 2011
- M.D., University of North Dakota, School of Medicine and Health Sciences, 2008
Grants
- Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib
- Randomized, Double-Blind, Placebo-Controlled Ph2 BLU-285 in Indolent and Smoldering Systemic
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3K? Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis
- A Phase I Trial of Incorporating Natural Killer (K-NK) cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease After Tyrosine Kinase Inhibitor (TKI) Therapy
- A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients with Essential Thrombocythemia
- Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
- Phase 2 study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3ss) inhibitor, as a single agent or combined with Ruxolitinib, in patients with myelofibrosis
- COVID-19 Phase 3 Assess Efficacy of Ruxolitinib
- BBI Ph1 TP-3654 and Ruxolitinb in patients with Intermediate and High Risk Myelofibrosis
- Targeting beta-arrestins in myeloid malignancies